Ghosh Ritam, Holland Ryan, Mammis Antonios
Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
World Neurosurg. 2017 Apr;100:712.e1-712.e4. doi: 10.1016/j.wneu.2017.01.073. Epub 2017 Jan 31.
Spinal cord stimulation has been used since 1967 to manage chronic neuropathic pain. Although effective, the literature describes the complication rate to be as high as 35%. One rare complication following spinal cord stimulator (SCS) implantation is the development of radicular pain. We present a case series of 2 patients implanted with SCSs who developed thoracic radiculopathy following implantation that resolved with corticosteroids.
Although this complication was previously thought to require surgical intervention, this case series describes the use of corticosteroids to resolve postimplantation thoracic radiculopathy. Two patients were studied in this case series who received permanent thoracic implantation of a paddle lead SCS. Several days later, both developed back pain radiating toward the umbilicus in a dermatomal pattern consistent with thoracic radiculopathy. Corticosteroids were administered to relieve this pain. One received 6 mg dexamethasone intravenously every 6 hours followed by an oral dexamethasone taper for 1 week. The other was treated with an oral methylprednisolone taper for 2 weeks.
Upon follow-up, both patients no longer complained of the thoracic radiculopathy and were satisfied with the pain relief the stimulators provided.
In conclusion, postsurgical radicular pain is a rare but troubling complication of SCS implantation. In order to avoid further surgical complications or the need to explant a device that provides satisfactory paresthesia coverage, pharmacologic management is desirable. This case series has demonstrated that the use of corticosteroids can effectively resolve postimplantation thoracic radicular pain in a specific subgroup of patients.
自1967年以来,脊髓刺激已被用于治疗慢性神经性疼痛。尽管有效,但文献报道其并发症发生率高达35%。脊髓刺激器(SCS)植入术后一种罕见的并发症是神经根性疼痛的发生。我们报告了2例植入SCS后发生胸段神经根病的病例系列,经皮质类固醇治疗后症状缓解。
尽管此前认为这种并发症需要手术干预,但该病例系列描述了使用皮质类固醇来缓解植入后胸段神经根病。本病例系列研究了2例接受永久性胸段植入桨状电极SCS的患者。几天后,两人均出现沿皮节分布向脐部放射的背痛,符合胸段神经根病的表现。给予皮质类固醇以缓解疼痛。其中1例每6小时静脉注射6毫克地塞米松,随后口服地塞米松逐渐减量,持续1周。另一例接受口服甲泼尼龙逐渐减量治疗2周。
随访时,两名患者均不再抱怨胸段神经根病,并对刺激器提供的疼痛缓解效果感到满意。
总之,术后神经根性疼痛是SCS植入罕见但令人困扰的并发症。为避免进一步的手术并发症或需要取出提供满意感觉异常覆盖的装置,药物治疗是可取的。该病例系列表明,皮质类固醇的使用可有效缓解特定亚组患者植入后胸段神经根性疼痛。